Skip to main content

Adding chemotherapy to gefitinib improves EGFR-mutated NSCLC outcomes

IV drip_patient's hand

Supplementing the EGFR–tyrosine kinase inhibitor gefitinib with pemetrexed and carboplatin doubles progression-free survival in patients with advanced, chemotherapy-naïve non-small-cell lung cancer harboring activating EGFR mutations, according to phase III results.


Monocyte counts could predict IPF outcome


Elevated monocyte counts are associated with poor outcomes among patients with idiopathic pulmonary fibrosis, suggest study findings published in The Lancet Respiratory Medicine.

Headlines from across medwireNews

25-06-2019 | Rheumatology | News | Article

Positive secukinumab results for axial manifestations in PsA

Secukinumab improves axial manifestations in patients with psoriatic arthritis and an inadequate response to nonsteroidal anti-inflammatory drugs, primary analysis of the phase III MAXIMISE trial shows.

25-06-2019 | Rheumatology | News | Article

Ixekizumab efficacious in PsA following one or two inadequate anti-TNF responses

Patients with psoriatic arthritis who have an inadequate response to one or two tumor necrosis factor inhibitors may benefit from ixekizumab, suggests research presented at the EULAR 2019 congress in Madrid, Spain.

25-06-2019 | Oncology | News | Article

Pembrolizumab approved in USA for metastatic SCLC

Click through for the details of this FDA decision

25-06-2019 | Oncology | News | Article

JAVELIN Renal 101 biomarker analysis may help personalize patient care

Biomarker analysis has given fresh insight into the response achieved with avelumab plus axitinib among advanced renal cell carcinoma patients participating in the JAVELIN Renal 101 trial.

25-06-2019 | Diabetes | News | Article

Stricter BP thresholds may be needed in type 1 diabetes

Findings from an observational cohort study suggest that a blood pressure target of 120/80 mmHg may be needed for effective prevention of coronary artery disease in people with type 1 diabetes.

24-06-2019 | Rheumatology | News | Article

Fasinumab may be a new option for osteoarthritic pain

The anti‐nerve growth factor monoclonal antibody fasinumab improves pain and function in patients with knee or hip osteoarthritis who have a history of inadequate response or intolerance to analgesics, study findings indicate.

medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make your preferred medical news resource.

Meet the team

Image Credits